What Happened?
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 24.8% in the afternoon session after the company announced the acquisition of Sigmund (marketed as Trybe Labs), which will allow it to introduce home lab testing through its platform. This capability is expected to help its subscribers test and identify diseases with more accuracy. The data generated from these new features is expected to support AI initiatives like MedMatch, which aim to improve treatment recommendations.
Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Hims & Hers Health’s shares are extremely volatile and have had 71 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business.
Hims & Hers Health is up 181% since the beginning of the year, and at $70.72 per share, has set a new 52-week high. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $7,002.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
